Regulatory diligence for fundraising, licensing and partnership
“What will a partner or investor actually look at, and what will make them reprice the deal?”
Regulatory diligence rarely kills a deal outright. It reprices it — because a gap that is discoverable in diligence is a cost the other side now knows about and you do not. The programmes that price well are not the ones with no gaps; they are the ones where every gap was already named, quantified and on a plan.
WHAT THIS IS NOT
Orientation for translating research toward a regulated product — not a determination of device status, regulatory pathway, submission type or clinical adequacy, and not a substitute for qualified regulatory advice. SPEQ is independent: linked institutions, incubators and agencies are third parties, and nothing here implies affiliation, endorsement or partnership with any of them.
ARE YOU HERE?
- A term sheet, a partnership or a licence is in prospect
- You know roughly where the weak spots are and they have not been written down
- Nobody has assembled the regulatory story end to end for an outside reader
WHAT TO DECIDE NOW
- What your own gap list is, before someone else builds it. The version you write is the version you can also cost and schedule.
- Which gaps are remediable before the transaction and which are disclosures, which is a different conversation with a different answer
- Who answers regulatory questions in the process, so the story does not vary between rooms
START KEEPING THESE RECORDS NOW
- A current, honest gap assessment with remediation status — the single most valuable document in a diligence process, and the one least often ready
- All regulator correspondence and meeting minutes, complete rather than curated; the gaps in a curated set are the first thing noticed
- Provenance for materials, data and IP, which is where transactions most often stall for reasons nobody anticipated
THE PROBLEM THIS ANSWERS
An investor, partner or acquirer tests whether the product can be defended by someone other than its inventor, and the organisation has the substance without the record that demonstrates it.
What it costs: Weeks of diligence rework at the moment of maximum leverage loss, and a discount applied to whatever cannot be quickly evidenced.
NOT YET MEASURED — Capital-map runs clustering ahead of a funding cycle rather than spreading evenly across the year.
WHERE THIS GOES WRONG
- Presenting the programme as further along than it is. Diligence is designed to find that, and being wrong about your own status damages more than the gap did.
- Having no written gap assessment. Its absence reads as either not knowing or not saying, and both are priced.
- Discovering material or data provenance problems during diligence. They are slow to fix and very visible.
WHAT THIS DOES NOT ANSWER
- What a specific counterparty will treat as material, which varies by acquirer and by deal structure
- Whether a gap is better remediated or disclosed, which is commercial as much as regulatory
OFFICIAL SOURCES · INDEPENDENT THIRD PARTIES
GO DEEPER ON SPEQ